Pharma BD Deal Intelligence
Gilead Sciences, Inc. / Sprint Bioscience AB
2025 · Asset Purchase · $414M · Complete
Sprint Bioscience agreed to sell its preclinical TREX1 oncology program to Gilead Sciences. Gilead pays USD 14 million upfront and up to USD 400 million in additional clinical, regulatory and commercial milestone payments. The program targets the TREX1 exonuclease, inhibition of which is intended to unleash innate anti-tumor immune activity.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Nov 24, 2025
- Deal value $414M
- Deal type Asset Purchase
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · Gilead Sciences, Inc. deals